End-of-life anticancer treatment - a nationwide registry-based study of trends in the use of chemo-, endocrine, immune-, and targeted therapies

CONCLUSIONS: We found a stable overall rate at 16% of patients receiving anticancer treatment within one month prior to death in this nationwide sample of cancer deaths. Further research is needed to assess whether this level of end-of-life treatment is justified or reflects inappropriate use.PMID:33651643 | DOI:10.1080/0284186X.2021.1890332

Source: Acta Oncologica - March 2, 2021 Category: Cancer & Oncology Authors: Thea Otto Mattsson Anton Potteg ård Trine Lembrecht J ørgensen Anders Green Mette Bliddal Source Type: research